Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Galantamine on Smoking Abstinence

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01548638
First received: March 5, 2012
Last updated: July 1, 2014
Last verified: June 2014

March 5, 2012
July 1, 2014
February 2012
August 2012   (final data collection date for primary outcome measure)
Number of Days of Abstinence During a 7-day Quit Attempt [ Time Frame: Days 36-43; following a 5-week dose run-up ] [ Designated as safety issue: No ]
Participants will undergo a 6-week study medication period. Day 36 will be the beginning of a 7-day practice quit attempt, during which number of days of abstinence will be assessed.
Same as current
Complete list of historical versions of study NCT01548638 on ClinicalTrials.gov Archive Site
  • Cognitive Performance: Working Memory Reaction Time [ Time Frame: At Baseline (Day 0), Day 35 (Day before Target Quit Day), and Day 43 ] [ Designated as safety issue: No ]

    Participants will complete neurocognitive test designed to test working memory and attention and are similar to computer games, in that participants will push a button in response to the pictures they see. Working memory was measured using a computerized N-back task. During the N-back, participants are instructed to remember the location of a stimulus, a grey circle that is approximately 5 cm in diameter, as it appears randomly in 8 possible locations around the perimeter of a computer screen. Stimulus duration is 200 ms, followed by an interstimulus interval (ISI) of 2800 ms. The N-back task includes 4 conditions of varying difficulty levels: the 0-back, 1-back, 2-back, and 3-back.

    Median reaction time to correct responses is described below.

    Typical responses range from 250 ms to 1500 ms.

  • Cognitive Performance: Working Memory Accuracy [ Time Frame: At Baseline (Day 0), Day 35 (Day before Target Quit Day), and Day 43 ] [ Designated as safety issue: No ]

    Participants will complete neurocognitive test designed to test working memory and attention and are similar to computer games, in that participants will push a button in response to the pictures they see. Working memory was measured using a computerized N-back task. During the N-back, participants are instructed to remember the location of a stimulus, a grey circle that is approximately 5 cm in diameter, as it appears randomly in 8 possible locations around the perimeter of a computer screen. Stimulus duration is 200 ms, followed by an interstimulus interval (ISI) of 2800 ms. The N-back task includes 4 conditions of varying difficulty levels: the 0-back, 1-back, 2-back, and 3-back.

    Number of correct responses (true positives) is described below.

    The maximum number of correct responses is 60.

  • Subjective Symptoms - Smoking Behavior, Urges, Mood, Nicotine Withdrawal [ Time Frame: Days 7, 14, 21, 28, 35, and 43; Baseline session ] [ Designated as safety issue: No ]
    The subjective symptoms listed above will be assessed at the following in-person sessions: Baseline session, Days 7, 14, 21, and 28 (brief monitoring visits), Day 35 (Day before Target Quit Day), and Days 37, 39, and 43 (during the 7-day quit attempt).
  • Side Effects of Galantamine [ Time Frame: Days 7, 14, 21, 28, 35, 37, 39, and 43; Baseline session ] [ Designated as safety issue: Yes ]

    Side effects of galantamine were assessed at the following in-person sessions: Baseline session, Days 7, 14, 21, and 28 (brief monitoring visits), Day 35 (Day before Target Quit Day), and Days 37, 39, and 43 (during the 7-day quit attempt). A 37-item checklist of side effects based on the product insert (e.g., Nausea, Vomiting, Diarrhea, Loss of appetite, Stomach pain, Constipation, Gastroesophageal Reflux Problems (Heartburn)) was administered to participants at all study visits after the Intake. An open-ended side effects question was also be included.

    Items were measured on a scale from 0 (None) to 3 (Severe).

    The side effect summary score (total side effects averaged from the 37 item checklist) at each visit is reported below. Each score ranges from 0 (None) to 3 (Severe).

  • Cognitive performance [ Time Frame: At Baseline (Day 0), Day 35 (Day before Target Quit Day), and Day 43 ] [ Designated as safety issue: No ]
    Participants will complete neurocognitive test designed to test working memory and attention and are similar to computer games, in that participants will push a button in response to the pictures they see.
  • Subjective symptoms - smoking behavior, urges, mood, nicotine withdrawal [ Time Frame: Days 7, 14, 21, 28, 35, and 43; Baseline session ] [ Designated as safety issue: No ]
    The subjective symptoms listed above will be assessed at the following in-person sessions: Baseline session, Days 7, 14, 21, and 28 (brief monitoring visits), Day 35 (Day before Target Quit Day), and Days 37, 39, and 43 (during the 7-day quit attempt).
  • Side effects of galantamine [ Time Frame: Days 7, 14, 21, 28, 35, and 43; Baseline session ] [ Designated as safety issue: Yes ]
    Side effects of galantamine will be assessed at the following in-person sessions: Baseline session, Days 7, 14, 21, and 28 (brief monitoring visits), Day 35 (Day before Target Quit Day), and Days 37, 39, and 43 (during the 7-day quit attempt).
Not Provided
Not Provided
 
Effect of Galantamine on Smoking Abstinence
The Effect of the Acetylcholinesterase Inhibitor, Galantamine, on Short-term Abstinence

This is a preliminary open-label study to determine whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.

Galantamine, an FDA-approved treatment for Alzheimer's disease, is used to treat cognitive impairment by enhancing acetylcholine through inhibition of the enzyme, acetylcholinesterase. We propose an open-label pilot feasibility study of short-term (6 weeks) treatment with galantamine.

Sixteen chronic smokers will undergo a validated procedure for screening new medications. Following an initial 4-week drug run-up phase (8mg daily of galantamine-ER), medication dose will be increased to 16 mg daily of galantamine-ER during the fifth and sixth weeks of the study. At the beginning of Week 6, smokers will receive brief counseling and make a 7-day quit attempt.

Following completion of the study, participants will be offered standard smoking cessation treatment. Subjects will perform a working memory task (Visual/Spatial N-Back), a sustained attention task (Continuous Performance Task; CPT), a recall memory task (Word Recognition), a cognitive flexibility task (Wisconsin Card Sort Test), and a response inhibition task (Stop Signal Task). The primary outcome is the ability to remain abstinent during a 7-day quit attempt. Secondary outcomes include change in cognitive performance, adherence, and side effects.

This pilot study will provide information about the role of the cholinergic system during brief abstinence and whether enhancing acetylcholine reduces abstinence-induced cognitive symptoms that promote smoking relapse. Information obtained in this study may further establish cognitive performance measures as endophenotypes for nicotine dependence.

Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Nicotine Addiction
Drug: Galantamine ER

The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.

Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER.

Other Name: Razadyne ER
Experimental: Galantamine ER
The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.
Intervention: Drug: Galantamine ER
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
13
October 2013
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Smokers who are between 18 and 60 years of age who self-report smoking at least 10 cigarettes (menthol and non-menthol) per day for at least the last 6 months.
  2. Healthy as determined by the Study Physician, based on a medical evaluation including medical history and physical examination, and psychiatric evaluation.
  3. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the combined consent and Health Insurance Portability and Accountability Act (HIPAA) form.
  4. Women of childbearing potential must consent to use a medically accepted method of birth control while participating in the study (e.g., condoms and spermicide, oral contraceptive, Depo-provera injection, contraceptive patch, tubal ligation).

Exclusion Criteria:

  1. Smoking Behavior

    • Use of chewing tobacco, snuff, and/or snus.
    • Current enrollment in a smoking cessation program, or use of other smoking cessation medications in the last month or plans to do either in the next 2 months.
    • Provide a carbon monoxide (CO) breath sample reading less than 10ppm at Medical Screening or Baseline visit.
  2. Alcohol/Drugs

    • Lifetime history of substance abuse (other than nicotine) and/or currently receiving treatment for substance abuse (e.g., alcohol, opioids, cocaine, stimulants, Phencyclidine (PCP), benzodiazepines, or study prohibited medications/recreational drugs) as determined by self-report during the phone screen and/or through the MINI during the Medical Screening.
    • Current alcohol consumption that exceeds 25 standard drinks/week over the past 6 months.
    • Providing a breath alcohol concentration (BrAC) reading of greater than or equal to 0.01 at Medical Screen or Baseline sessions.
    • A positive urine drug screen for cocaine, amphetamines, methamphetamines, benzodiazepines, PCP, methadone, barbiturates, and opiates at the Medical Screening, Baseline visit, and Testing days.
  3. Medical

    • Women who are pregnant, planning a pregnancy in the next 3 months, or lactating; all female subjects of child-bearing potential shall undergo a urine pregnancy test prior to enrollment and must agree in writing to use an approved method of contraception. Pregnancy tests will be conducted at the Medical Screening, Baseline visit, and Testing days.
    • Diagnosis of Alzheimer's Disease or dementia.
    • Current treatment of cancer or diagnosed with cancer (except basal cell carcinoma) in the past 6 months.
    • Liver/kidney failure, peptic ulcer disease, benign prostate hypertrophy
    • Asthma or chronic obstructive pulmonary disease (COPD)
    • History (last 6 months) of abnormal heart rhythms, tachycardia and/or cardiovascular disease (stroke, angina, heart attack).
    • Serious or unstable disease within the past 6 months, as determined by the Study Physician.
    • Any impairment (physical and/or neurological) including visual or other impairment preventing cognitive task performance.
    • Uncontrolled high blood pressure (systolic>150 or diastolic>90)
    • Hearing impairment, significant hearing loss (more than 20% in either ear), cochlear implants, or bi-lateral hearing aids.
    • History of brain injury.
    • History of epilepsy or a seizure disorder.
    • Color Blindness.
    • Low or borderline intellectual functioning - determined by receiving a score of less than 90 on the Shipley Institute of Living Scale (SILS) which correlates with the Wechsler Adult Intelligence Scale-Revised (WAIS-R) Estimated Intelligence Quotient (IQ) Test (administered at Medical Screening).
  4. Psychiatric Exclusion (as determined by self-report on phone screen and/or through MINI during Medical Screening)

    • Current diagnosis of major depression. Persons with a history of major depression, in remission for 6 months or longer, are eligible, provided they are not excluded based on medications (below).
    • Suicide risk score on MINI greater than 0.
    • History or current diagnosis of schizophrenia, psychosis, or bipolar disorder.
    • Current or past hypomanic/manic episode.
    • Current or history of a diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD).
  5. Medication

    • Current use, recent discontinuation (within the last month) of any form of smoking cessation medications (i.e., Zyban, Wellbutrin, Wellbutrin sustained-release (SR), Chantix, nicotine replacement therapy).
    • Current use, recent discontinuation (within the last 60 days) or planned use of the following medications:
    • Anti-anxiety or panic disorder medications.
    • Anti-psychotic medications.
    • Mood-stabilizers (Lithium, Lamictal/lamotrigine, Neurontin/gabapentin, Topamax/topiramate, valproic acid, Tegretol/carbamazepine)
    • Anti-depressants (e.g., Wellbutrin, monoamine oxidase inhibitor (MAOIs), selective serotonin reuptake inhibitor (SSRIs), tricyclic antidepressants).
    • Prescription stimulants (e.g., Provigil, Ritalin, Adderall).
    • Systemic Steroids (e.g., Prednisone).
    • Current use (or use in the past 60 days) of:
    • Alzheimer's disease medications (e.g., Acetylcholinesterase inhibitors (ACIs), Aricept/donepezil, Exelon/rivastigmine, Tacrine, or memantine).
    • Parkinson's disease medications(e.g., Cogentin/benztropine).
    • Irritable bowel syndrome medication (e.g., Dicylomine/Bentyl).
    • Heart medications (e.g., quinidine or Procardia/nifedipine).
    • Peptic ulcer disease medication (e.g, Zantac/ranitidine).
    • Muscle relaxants (e.g., Soma/carisoprodol, Anectine/succinylcholine).
    • Anti-fungal medication (e.g., Nizoral/ketoconazole).
    • Anti-seizure medications (e.g., Ativan, Banzel, Carbatrol, Dilantin, Lamictal, Gabitril, Lyrica, Neurontin, Tegretol, Topamax).
    • COPD medication (e.g., Atrovent/Ipratropium Bromide).
    • Blood pressure medication (e.g., Inversine/Mecamylamine).
    • Urinary retention medications (Duvoid/bethanechol, Proscar/finasteride, Avodart/dutasteride, Dibenzyline/phenoxybenzamine, Regitine/phentolamine).
    • Eye medication (e.g., Atropine).
    • Daily use of:
    • Opiate-containing medications for chronic pain (Duragesic/fentanyl patches, Percocet, Oxycontin).
    • Medication for asthma (albuterol, Serevent, Combivent, Advair, Flovent, Azmacort, Symbicort).
    • Known allergy to study medication.
    • Participants shall be instructed to refrain from using any study prohibited drugs (note - participants are allowed to take prescription medicines not in the exclusion list) throughout their participation in the study.
  6. General Exclusion

    • Current enrollment or plans to enroll in another research program in the next 2 months.
    • Any medical condition, illness, disorder, or concomitant medication that could compromise participant safety or treatment, as determined by the Principal Investigator and/or Study Physician.
    • Inability to provide informed consent or complete any of the study tasks as determined by the Principal Investigator.
    • Completion of cognitive testing in studies in our center within the last 6 months.
    • Able to effectively communicate in English (reading, writing, speaking).
    • Missing 2 or more consecutive sessions, or 3 or more sessions during the medication period.
    • Missing 2 or more consecutive doses during the medication period.
    • Missing 3 or more doses throughout the medication period.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01548638
814947
No
University of Pennsylvania
University of Pennsylvania
Not Provided
Principal Investigator: Rebecca Ashare, Ph.D. University of Pennsylvania
University of Pennsylvania
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP